Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;3(2):100149.
doi: 10.1016/j.jcvp.2023.100149. Epub 2023 Apr 21.

SARS-CoV-2 evolution during persistent infection in a CAR-T recipient shows an escape to both sotrovimab and T-cell responses

Paola Mazzetti  1 , Pietro Giorgio Spezia  2 , Anna-Lisa Capria  1 , Giulia Freer  2 , Maria Sidoti  1   2 , Silvia Costarelli  3 , Alice Cara  1 , Alfredo Rosellini  1 , Susi Frateschi  1 , Giovanna Moscato  1 , Iacopo Franconi  1 , Michele Curcio  4 , Maria Linda Vatteroni  1 , Michele Lai  2 , Paola Quaranta  2 , Daniele Focosi  5 , Spartaco Sani  3 , Mauro Pistello  1   2
Affiliations

SARS-CoV-2 evolution during persistent infection in a CAR-T recipient shows an escape to both sotrovimab and T-cell responses

Paola Mazzetti et al. J Clin Virol Plus. 2023 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interests.

Figures

Fig 1
Fig. 1
Timeline outlining the key events in the study patient's SARS-CoV-2 infections. The red arrows indicate the times when PCR on nasopharyngeal swab (NPS) tested positives, either through antigenic or molecular assays, and when viral isolation and/or sequencing were performed. Additional details on the results of antigenic and molecular assays, whole genome sequencing, and immunological analyses are available in Supplementary Tables 1 and 2.
See this image and copyright information in PMC

References

    1. Bartolini B., Rueca M., Gruber C.E.M., Messina F., Carletti F., Giombini E., Lalle E., Bordi L., Matusali G., Colavita F., et al. SARS-CoV-2 phylogenetic analysis, lazio region, Italy, February-March 2020. Emerging Infect. Dis. 2020;26:1842–1845. doi: 10.3201/eid2608.201525. - DOI - PMC - PubMed
    1. Destras G., Bal A., Simon B., Lina B., Josset L. Sotrovimab drives SARS-CoV-2 Omicron variant evolution in immunocompromised patients. Lancet Microbe. 2022;3 doi: 10.1101/2022.04.08.22273513. %J medRxiv. - DOI - PMC - PubMed
    1. Focosi D., Novazzi F., Baj A., Ferrante F.D., Boutahar S., Genoni A.P., Gasperina D.D., Maggi F. Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: a series of three cases. J. Clin. Virol. Plus. 2022;2 doi: 10.1016/j.jcvp.2022.100097. - DOI - PMC - PubMed
    1. Rockett R.J., Basile K., Maddocks S., Fong W., Agius J.E., Johnson-Mackinnon J., Arnott A., Chandra S., Gall M., Draper J.L., et al. Resistance mutations in SARS-CoV-2 Delta variant after sotrovimab use. N. Engl. J. Med. 2021;386:1477–1479. doi: 10.1056/NEJMc2120219. - DOI - PMC - PubMed
    1. Vellas C., Trémeaux P., Del Bello A., Latour J., Jeanne N., Ranger N., Danet C., Martin-Blondel G., Delobel P., Kamar N., et al. Resistance mutations in SARS-CoV-2 Omicron variant in patients treated with sotrovimab. Clin. Microbiol. Infect. 2022;28:1297–1299. doi: 10.1016/j.cmi.2022.05.002. - DOI - PMC - PubMed

LinkOut - more resources